Cargando…

Marine drugs as putative inhibitors against non-structural proteins of SARS-CoV-2: an in silico study

INTRODUCTION: Coronavirus disease 2019 (COVID-19) is an unprecedented pandemic, threatening human health worldwide. The need to produce novel small-molecule inhibitors against the ongoing pandemic has resulted in the use of drugs such as chloroquine, azithromycin, dexamethasone, favipiravir, ribavir...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Simran, Hasan, Haydara, Umraliya, Divyesh, Sanapalli, Bharat Kumar Reddy, Yele, Vidyasrilekha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176293/
https://www.ncbi.nlm.nih.gov/pubmed/37171714
http://dx.doi.org/10.1007/s00894-023-05574-9
_version_ 1785040401157062656
author Patel, Simran
Hasan, Haydara
Umraliya, Divyesh
Sanapalli, Bharat Kumar Reddy
Yele, Vidyasrilekha
author_facet Patel, Simran
Hasan, Haydara
Umraliya, Divyesh
Sanapalli, Bharat Kumar Reddy
Yele, Vidyasrilekha
author_sort Patel, Simran
collection PubMed
description INTRODUCTION: Coronavirus disease 2019 (COVID-19) is an unprecedented pandemic, threatening human health worldwide. The need to produce novel small-molecule inhibitors against the ongoing pandemic has resulted in the use of drugs such as chloroquine, azithromycin, dexamethasone, favipiravir, ribavirin, remdesivir and azithromycin. Moreover, the reports of the clinical trials of these drugs proved to produce detrimental effects on patients with side effects like nephrotoxicity, retinopathy, cardiotoxicity and cardiomyopathy. Recognizing the need for effective and non-harmful therapeutic candidates to combat COVID-19, we aimed to develop promising drugs against SARS-COV-2. DISCUSSION: In the current investigation, high-throughput virtual screening was performed using the Comprehensive Marine Natural Products Database against five non-structural proteins: Nsp3, Nsp5, Nsp12, Nsp13 and Nsp15. Furthermore, standard precision (SP) docking, extra precision (XP) docking, binding free energy calculation and absorption, distribution, metabolism, excretion and toxicity studies were performed using the Schrӧdinger suite. The top-ranked 5 hits obtained by computational studies exhibited to possess a greater binding affinity with the selected non-structural proteins. Amongst the five hits, CMNPD5804, CMNPD20924 and CMNPD1598 hits were utilized to design a novel molecule (D) that has the capability of interacting with all the key residues in the pocket of the selected non-structural proteins. Furthermore, 200 ns of molecular dynamics simulation studies provided insight into the binding modes of D within the catalytic pocket of selected proteins. CONCLUSION: Hence, it is concluded that compound D could be a promising inhibitor against these non-structural proteins. Nevertheless, there is still a need to conduct in vitro and in vivo studies to support our findings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00894-023-05574-9.
format Online
Article
Text
id pubmed-10176293
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-101762932023-05-14 Marine drugs as putative inhibitors against non-structural proteins of SARS-CoV-2: an in silico study Patel, Simran Hasan, Haydara Umraliya, Divyesh Sanapalli, Bharat Kumar Reddy Yele, Vidyasrilekha J Mol Model Original Paper INTRODUCTION: Coronavirus disease 2019 (COVID-19) is an unprecedented pandemic, threatening human health worldwide. The need to produce novel small-molecule inhibitors against the ongoing pandemic has resulted in the use of drugs such as chloroquine, azithromycin, dexamethasone, favipiravir, ribavirin, remdesivir and azithromycin. Moreover, the reports of the clinical trials of these drugs proved to produce detrimental effects on patients with side effects like nephrotoxicity, retinopathy, cardiotoxicity and cardiomyopathy. Recognizing the need for effective and non-harmful therapeutic candidates to combat COVID-19, we aimed to develop promising drugs against SARS-COV-2. DISCUSSION: In the current investigation, high-throughput virtual screening was performed using the Comprehensive Marine Natural Products Database against five non-structural proteins: Nsp3, Nsp5, Nsp12, Nsp13 and Nsp15. Furthermore, standard precision (SP) docking, extra precision (XP) docking, binding free energy calculation and absorption, distribution, metabolism, excretion and toxicity studies were performed using the Schrӧdinger suite. The top-ranked 5 hits obtained by computational studies exhibited to possess a greater binding affinity with the selected non-structural proteins. Amongst the five hits, CMNPD5804, CMNPD20924 and CMNPD1598 hits were utilized to design a novel molecule (D) that has the capability of interacting with all the key residues in the pocket of the selected non-structural proteins. Furthermore, 200 ns of molecular dynamics simulation studies provided insight into the binding modes of D within the catalytic pocket of selected proteins. CONCLUSION: Hence, it is concluded that compound D could be a promising inhibitor against these non-structural proteins. Nevertheless, there is still a need to conduct in vitro and in vivo studies to support our findings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00894-023-05574-9. Springer Berlin Heidelberg 2023-05-12 2023 /pmc/articles/PMC10176293/ /pubmed/37171714 http://dx.doi.org/10.1007/s00894-023-05574-9 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Paper
Patel, Simran
Hasan, Haydara
Umraliya, Divyesh
Sanapalli, Bharat Kumar Reddy
Yele, Vidyasrilekha
Marine drugs as putative inhibitors against non-structural proteins of SARS-CoV-2: an in silico study
title Marine drugs as putative inhibitors against non-structural proteins of SARS-CoV-2: an in silico study
title_full Marine drugs as putative inhibitors against non-structural proteins of SARS-CoV-2: an in silico study
title_fullStr Marine drugs as putative inhibitors against non-structural proteins of SARS-CoV-2: an in silico study
title_full_unstemmed Marine drugs as putative inhibitors against non-structural proteins of SARS-CoV-2: an in silico study
title_short Marine drugs as putative inhibitors against non-structural proteins of SARS-CoV-2: an in silico study
title_sort marine drugs as putative inhibitors against non-structural proteins of sars-cov-2: an in silico study
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176293/
https://www.ncbi.nlm.nih.gov/pubmed/37171714
http://dx.doi.org/10.1007/s00894-023-05574-9
work_keys_str_mv AT patelsimran marinedrugsasputativeinhibitorsagainstnonstructuralproteinsofsarscov2aninsilicostudy
AT hasanhaydara marinedrugsasputativeinhibitorsagainstnonstructuralproteinsofsarscov2aninsilicostudy
AT umraliyadivyesh marinedrugsasputativeinhibitorsagainstnonstructuralproteinsofsarscov2aninsilicostudy
AT sanapallibharatkumarreddy marinedrugsasputativeinhibitorsagainstnonstructuralproteinsofsarscov2aninsilicostudy
AT yelevidyasrilekha marinedrugsasputativeinhibitorsagainstnonstructuralproteinsofsarscov2aninsilicostudy